Exploring the Pharmacological Mechanisms of <i>Tripterygium wilfordii</i> Hook F against Cardiovascular Disease Using Network Pharmacology and Molecular Docking

Huang, Bingwu; Huang, Chengbin; Zhu, Liuyan; Xie, Lina; Wang, Yi; Zhu, Ning

doi:https://doi.org/10.1155/2021/5575621

BioMed Research International

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusion Data Availability Disclosure Conflicts of Interest Authors’ Contributions Acknowledgments Supplementary Materials References Copyright Related Articles

Research Article | Open Access

Volume 2021 | Article ID 5575621 | https://doi.org/10.1155/2021/5575621

Exploring the Pharmacological Mechanisms of Tripterygium wilfordii Hook F against Cardiovascular Disease Using Network Pharmacology and Molecular Docking

Bingwu Huang,¹Chengbin Huang,²Liuyan Zhu,³Lina Xie,⁴Yi Wang,⁵and Ning Zhu⁵

Academic Editor: Rita Casadio

Received02 Feb 2021

Revised14 Jun 2021

Accepted19 Jul 2021

Published16 Aug 2021

Abstract

Background. Tripterygium wilfordii Hook F (TwHF) has been used in traditional Chinese medicine (TCM) for treating cardiovascular disease (CVD). However, the underlying pharmacological mechanisms of the effects of TwHF on CVD remain elusive. This study revealed the pharmacological mechanisms of TwHF acting on CVD based on a pharmacology approach. Materials and Methods. The active compounds were selected from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database according to the absorption, distribution, metabolism, and excretion (ADME). The potential targets of TwHF were obtained from the SwissTargetPrediction database. The CVD-related therapeutic targets were collected from the DrugBank, the GeneCards database, and the OMIM database. Protein–protein interaction (PPI) network was generated by the STITCH database. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed by R package. The network of drug-targets-diseases-pathways was constructed by the Cytoscape software. Results. The 41 effective ingredients of TwHF and the 178 common targets of TwHF and CVD-related were collected. Furthermore, AKT1, amyloid precursor protein (APP), mitogen-activated protein kinase 1 (MAPK), phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA), and cellular tumor antigen p53 (TP53) were identified as the core targets involved in the mechanism of TwHF on CVD. Top ten GO (biological processes, cellular components, and molecular functions) and KEGG pathways were screened with a value ≤0.01. Finally, we constructed the network of TwHF-targets-CVD-GO-KEGG. Conclusions. These findings demonstrate that the main active compound of TwHF, the core targets, and pathways maybe provide new insights into the development of a natural therapy for the prevention and treatment of CVD.

1. Introduction

Cardiovascular disease (CVD) is a collective term for cardiovascular and cerebrovascular diseases, which is the first cause of death in the world [1]. The burden of CVD is on the rise globally, especially in middle- and low-income countries (LMIC) [2, 3]. In 2013, the World Health Organization (WHO) proposed that countries should reduce premature mortality that related to noncommunicable diseases, including CVD, by 25% by 2025 [4]. Although Western medicines have made good progress in reducing the risk of cardiovascular events and total mortality, patients with long-term cardiovascular treatment still have difficult adherence that might lead to discontinuation of these drugs. This can be attributed to the adverse reactions caused by multiple pharmacologic agents and some drugs that beyond the affordability of LMIC [3, 5]. Traditional Chinese medicine (TCM), with thousands of years of history in China, has gained widespread clinical applications. In particular, TCM occupies a special position in their heart of the elderly. As a critical component of complementary and alternative medicine, TCM medications have been used for the prevention and treatment of CVD [6].

Tripterygium wilfordii Hook F (TwHF), also known as Leigongteng and Thunder God Vine, has possessed many pharmacological activities such as anticancer, anti-inflammation, antifibrosis, antiatherosclerosis, and antiautoimmune disorders [7–9]. Recently, several fundamental researches have indicated that low-dose TwHF can prevent cardiovascular diseases. Low-dose TwHF can improve the inflammatory reaction, reduce myocardial injury, and optimize acute coronary syndrome (ACS) rat’s condition with inhibition of myocardial apoptosis [10]. TwHF extracts were shown to have cardioprotection effects by inducing the activation of Nrf2/HO-1 defense pathway, inhibiting the activation of NF-κB pathway and reducing the expression of NLRP3 inflammasome [11–13]. In addition, the extracts can not only improve the vascular function in atherosclerosis, but also may help in the prevention of in-stent restenosis formation following endovascular treatment of lower-extremity artery disease [14, 15]. However, the underlying pharmacological mechanisms of the effects of TwHF on CVD remain elusive.

Network pharmacology is an innovative way to analyze the complicated relationship between drugs and disease at the system level, which can provide clues for discovering new drugs [16]. This approach integrates and constructs the complicated networks among drug targets, disease targets, and biological processes [17]. It is possible to reveal potential drug-target-disease interactions and realize novel therapeutic application beyond the TCM application through network pharmacology [18]. In this study, target prediction, pharmacokinetic evaluation, molecular structure, biological function, and pathway analysis using many available public databases and bioinformatics tools have systematically elucidated the mechanisms of therapeutic effects of TwHF on CVD (Figure 1).

2. Materials and Methods

2.1. Active Component Screening

Traditional Chinese Medicine Systems Pharmacology database (TCMSP, https://tcmspw.com/tcmsp.php) is an efficient pharmacology resource, which can be used to assess the pharmacokinetics of TCMs or related compounds [19]. It can provide the absorption, distribution, metabolism, and excretion (ADME) properties of compounds, the main indicators of which are oral bioavailability (OB) and drug similarity (DL). OB is a reliable indicator to evaluate the intrinsic quality of drugs objectively, which represents to the speed and degree of absorbing drugs into the circulatory system. And DL represents the sum of the pharmacokinetic properties and safety of compounds, which is calculated by comparing the functional or physical properties of the compounds with those of the majority of known drugs [20]. In this paper, the compound name “Leigongteng” was inputted to the TCMSP database, and active ingredients with and % were selected for subsequent analysis. Then, SMILES and PubChem ID of candidate components were collected by using the Traditional Chinese Medicines Integrated Database (TCMID, http://www.megabionet.org/tcmid/) [21] and the PubChem (https://pubchem.ncbi.nlm.nih.gov/) database [22].

2.2. Identified and Predicted Targets of TwHF

The targets of active components in TwHF were obtained from the SwissTargetPrediction (http://www.swisstargetprediction.ch), which is a free public resource used to accurately predict targets for bioactive molecules [23]. The therapeutic targets of active ingredients were predicted by inputting these components SMILES into SMILES string (s) and searching for their similar molecules. Within the range of “Homo sapiens,” high probability targets (probability ) were collected after duplicate contents were removed.

2.3. Target Identification of Known Therapeutic Targets Acting on CVD

The CVD-related therapeutic targets were collected from the DrugBank (http://www.drugbank.ca) [24], the OMIM database (https://omim.org) [25], and the GeneCards database (https://www.genecards.org) [26]. DrugBank is a freely available network database, which provides molecular information about drugs, drug targets, drug effects, and drug interactions. OMIM database, a comprehensive web resource, is focusing on genes, genetic phenotypes, and their relationships. In addition, GeneCards is a public database that provides detailed information on annotated and predicted genes. With “cardiovascular disease” as the keyword, CVD-related targets were searched among the three databases.

2.4. Protein–Protein Interaction (PPI) Network Construction and Analysis

The identified targets were uploaded to the STITCH database v5.0 (http://stitch.embl.de/) [27] to build the protein–protein interaction network and clarify the functional and physical association between them. The protein interactions were limited to a combined score of 0.9 or higher. The core target genes were determined based on the criterion of and the number of interactions.

2.5. GO and KEGG Pathway Enrichment Analyses

GO analysis can supply gene product biological function information and divide candidate targets into various functional modules, including cellular components (CCs), biological pathways (BPs), and molecular functions (MFs) [28]. KEGG analysis can give functional meaning to genes at molecular or higher levels [29]. Enrichment analyses of GO of core target genes and KEGG were performed by using R (version 3.6.0 for Windows). By using a cut-off value adjusted to , the top ten GO enrichments and KEGG pathways were screened.

2.6. Construction of Network Relationships

Cytoscape is a free application software, which can transform biomolecular interaction networks into a versatile and interactive visualization framework [30]. The core targets of TwHF on CVD were constructed for KEGG-GO enrichment visualization by the Cytoscape (v3.7.1) software [31]. In the interactive network, the nodes include TwHF, CVD, and their core targets, GO and KEGG pathways. Then, the edges represent the interaction between them.

2.7. Molecular Docking

The crystal structures of target proteins were collected from the RCSB Protein Data Bank (http://www.pdb.org/) and decorated by removing the ligands and water motifs, adding hydrogen, and optimizing the mutation sites by the PyMOL (version 2.3). The 3D chemical structural formulas of key ingredients were collected from PubChem and energy minimized by using ChemBioDraw 3D (version 14). The sites, binding ability, and interactions between compounds and targets were analyzed by PyMOL, AutoDockTools (version 1.5.6), and Discovery Studio 2020 Clients [32, 33]. Autodock vina (1.1.2) was used to conduct docking between compounds and target proteins.

3. Results

3.1. Active Ingredient Screening

Total of 51 effective ingredients of TwHF that satisfied and % were screened from TCMSP. But the structural formula of 41 effective ingredients of TwHF could be obtained from PubChem (https://www.ncbi.nlm.nih.gov/pccompound) for subsequent analysis (Table 1).

3.2. Target Identification of TwHF and CVD

Firstly, a total of 827 candidate targets of TwHF were downloaded from SwissTargetPrediction (Supplementary Table 1). Secondly, 76 known CVD-related targets were downloaded from the DrugBank database, 358 known CVD-related targets were downloaded from the GeneCards database, and 474 known CVD-related targets were downloaded from the OMIM database (Supplementary Table 1). Then, 802 CVD-related targets were identified by removing the repeated targets. Finally, the 178 common targets of the targets of CVD-related and TwHF were selected for subsequent analysis (Supplementary Table 1).

3.3. PPI Network Construction and Analysis

Firstly, the PPI network was generated by uploading these 178 identified targets to the STITCH database, and screening condition was limited to . Then, AKT1, amyloid precursor protein (APP), mitogen-activated protein kinase 1 (MAPK), phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA), and cellular tumor antigen p53 (TP53) were identified based on the number of interactions (Table 2). These five genes were considered the key putative targets involved in the effects of TwHF on CVD. The raw data () was shown in Supplementary Table 2.

3.4. GO and KEGG Pathway Enrichment Analyses

The 178 candidate targets were selected for GO and KEGG pathway enrichment analyses. The top ten GO analyses of biological process (BP), cellular component (CC), and molecular function (MF) categories were screened (Figure 2). As the results of GO enrichment, the enriched biological process categories were dominated by ERBB signaling pathway, regulation of generation of precursor metabolites and energy, peptidyl-serine phosphorylation, aging, peptidyl-serine modification, regulation of developmental growth, neuron death, regulation of DNA metabolic process, cellular response to peptide, and response to oxidative stress. CC analysis showed that the spindle was mainly accounted for the largest proportion. The enriched MF categories were dominated by phosphatase binding and protein serine/threonine kinase activity. The KEGG pathway analysis showed that these targets were mainly associated with cancer, melanoma, platinum drug resistance, glioma, chronic myeloid leukemia, endocrine resistance, sphingolipid signaling pathway, neurotrophin signaling pathway, thyroid hormone signaling pathway, apoptosis, cellular senescence, hepatitis C, and hepatitis B (Figure 3).

(a)

(b)

(c)

3.5. Construction of Network

The network visualization of TwHF-targets-CVD-GO-KEGG was generated by using the Cytoscape software (Figure 4).

3.6. Molecular Docking

The crystal structures of potential targets, including AKT1 (PDB: 6CCY; 2.18 Å), APP (PDB: 5BUO; 2.31 Å), MAPK1 (PDB: 6SIG; 1.58 Å), PIK3CA (PDB: 4TTU; 2.18 Å), and TP53 (PDB: 6RZ3; 4.23 Å) were collected (Figure 5). Other detail of protein structure could be also found in RCSB Protein Data Bank. Figure 5 showed celaxanthin binds to AKT1 with a binding pocket consisting of SER-240 (2.9 Å); hypodiolide A fails to bind to APP without a binding pocket; triptofordin B2 binds to MAPK1 with a binding pocket consisting of SER-153 (3.3 Å) and ARG-155 (3.3 Å); triptofordin B2 binds to PIK3CA with a binding pocket consisting of GLN-582 (3.1 Å); celallocinnine binds to TP53 with a binding pocket consisting of LEU-111 (3.2 and 3.0 Å), ASN-131 (3.1 Å), and TYR-126 (2.9 Å).

(a)

(b)

(c)

(d)

(e)

4. Discussion

There is an urgent need to promote new drugs for CVD treatment because of the heavy burden of CVD and the poor efficacy and side effects of the currently used medicines. Network pharmacology was applied to reveal the interaction between medicines and targets of diseases, and it can comprehensively describe the complexity between drugs and diseases [33, 34]. Therefore, the use of network pharmacology uncovering multiple drug-target interactions may contribute to novel drug discovery in complex diseases such as CVD. TwHF exhibits therapeutic efficacy in preclinical models of CVD and has been identified in several studies [35–37]. In the present study, the underlying mechanism of the protective effects of TwHF on CVD was uncovered by a network pharmacology strategy. Therapeutic targets and signaling pathways were investigated by database screening, PPI network construction, and pathway enrichment analysis. Furthermore, to validate the specific interactions between core targets and CVD, molecular docking was conducted.

In this study, 41 active compounds of TwHF were determined based on ADME. Pharmacological analysis suggested that these active components may have protective effects against CVD. Nobiletin has been reported to attenuate hypoxia/reoxygenation-induced injury by the inhibition of oxidative stress and apoptosis in H9c2 cardiomyocytes, as well as myocardial ischemia and reperfusion injury in vivo [38, 39]. Triptonide ameliorates diabetic cardiomyopathy via mediating inflammation [40, 41]. Isoxanthohumol regulates vivo vascular proliferation and in vivo—the inflammatory crosstalk of vascular cells, contributing to the treatment of angiogenesis and inflammation-related diseases [42]. Stigmasterol blocked Ang II-induced aortic smooth muscle cell proliferation by the arrest of the cell-cycle and promoted apoptosis and ROS production [43]. Kaempferol attenuates cardiac hypertrophy and isoproterenol-induced heart failure in diabetic rats [44, 45].

Subsequently, the targets of TwHF and CVD were also identified. 178 common candidate targets between TwHF and CVD were selected. Finally, we screened 5 core candidate genes for further analysis. The interactive values and interaction indicate that these targets are closely contacted with other targets in “CVD-target PPI network” and are responsible for TwHF acting on CVD and the pathogenesis of CVD. As was well known, Akt signaling plays an important role in many processes of CVD pathology such as atherosclerosis, vascular remodeling, and cardiac hypertrophy. Several Akt inhibitors have been proven to be potential novel therapeutics for the CVD [46]. PIK3R1, MAPK1, and PIK3CA may modulate platelet activation and be involved in CVD [47]. Class I phosphatidylinositol 3-kinases (PI3Ks) are composed of a regulatory subunit (p85 regulatory subunit) and a catalytic subunit (p110 catalytic subunit) [48, 49]. The catalytic subunit p110α of PI3K is encoded by the gene PIK3CA, which regulates doxorubicin-induced cardiotoxicity [50]. Indeed, the compounded cardiovascular risk of PI3Kα inhibitor use in breast cancer is particularly relevant given the prevalence of p110α gain-of-function mutations [51]. p38 mitogen-activated protein kinase (p38), extracellular signal-regulated kinase1/2 (ERK), and c-Jun NH2 terminal protein kinase (JNK) are major components of MAPK kinases, which control embryogenesis, differentiation, proliferation, and death [52]. The inactivation of JNK, p38MAPK, and ERK1/2 could block vascular smooth muscle cell proliferation and migration [53–55]. APP is associated with the adhesion of platelets to amyloid peptides and thrombus formation [56, 57]. It was reported TP53 can differentiate patients with left main coronary artery disease from healthy participants [58].

Top ten GO of each category (BP, MF, and CC) and KEGG pathways associated with TwHF acting on CVD were classified. These categories composed of the most key targets are considered specific and meaningful enrichment. The data showed that the major components were mainly related with multiple BPs, such as ERBB signaling pathway, regulation of generation of precursor metabolites and energy, peptidyl-serine phosphorylation, aging, peptidyl-serine modification, regulation of developmental growth, neuron death, regulation of DNA metabolic process, cellular response to peptide, and response to oxidative stress. It is reported that ERBB signaling can regulate cardiovascular development and multiple cardiac cell biology [59, 60]. Regulation of developmental growth and regulation of DNA metabolic process suggested TwHF acting on CVD through cardiovascular proliferation. However, BPs including precursor metabolites and energy, peptidyl-serine phosphorylation, neuron death, and cellular response to peptide have not been well investigated. Further studies should be conducted to determine the role of these BPs. The major components acting on CVD were also associated with spindle in terms of CC, which indicated TwHF acting on CVD was associated with regulation of the proliferation and differentiation of cardiovascular cells. The enriched MF categories were dominated by phosphatase binding and protein serine/threonine kinase activity. Various phosphatases promoted vascular remodeling and pulmonary arterial hypertension by modulating smooth muscle cell proliferation [61, 62]. Many serine-threonine kinases, such as P-21-activated kinases, PAKs, or RhoA/Rho-kinase, have been well demonstrated to promote the development of CVD [63, 64]. It was reported that there was a strong crosstalk between oxidative stress and various CVDs, including atherosclerosis, myocardial ischemia, ischemia reperfusion injury, and drug-induced cardiotoxicity [65, 66]. In addition, oxidative stress regulates multiple cardiovascular functions, such as cell proliferation and death [67]. KEGG pathway enrichment analysis showed TwHF may exert protective effects on CVD mainly by cancer pathways. Cancer and cardiovascular disease (CVD) share overlapping pathophysiology and risk factors as well as biological mechanisms [68]. Protein–protein interaction analysis has varied roles in driving and maintaining the growth of cancer and CVD [69, 70]. TwHF was also determined as an efficacy treatment of multiple cancers [71–73]. In summary, GO and KEGG pathway enrichments indicated that TwHF exerting protective effects on CVD probably through modulation of the proliferation of cardiovascular system cells.

According to the screening criteria of high OB, celaxanthin, hypodiolide A, triptofordin B2, and celallocinnine were chosen for the compound-ligand interaction analysis by molecular docking to validate the effects of TwHF acting on CVD. The results of molecular docking reflected that these active compounds possess suitable anti-CVD activity. However, to verify the active properties of TwHF and the molecular target genes of anti-CVD, further experimental studies need to be performed.

5. Conclusion

In summary, the network pharmacology method was performed to unveil the chemical basis and investigate the action mechanism of TwHF on CVD. Firstly, 41 active compounds of TwHF and 5 core target genes (AKT1, APP, MAPK, PIK3CA, and TP53) of TwHF against CVD were identified. Then, based on the analysis of GO and KEGG, the cancer pathway was found to be closely associated with the protective effect of TwHF on CVD. It provides a theoretical basis and a clue for the pharmacological mechanism study of TwHF on CVD in this study.

5.1. Limitation

There are some limitations to this study. Because of the collection of targets from databases, the predicted targets might be inaccurate and specific. Other values of compounds might be also inaccurate, such as the OB value of triptofordin B2, which is greater than 100%. These values also were predicted by chemometric method. Therefore, further experimental studies of these prediction results are needed to validate the potential applications.

Data Availability

The data used to support the findings of this study are included within the article and the supplementary files.

Disclosure

This manuscript was submitted as a preprint in the link “https://www.researchsquare.com/article/rs-151905/v1.”

Conflicts of Interest

The authors report no relationships that could be construed as a conflict of interest.

Authors’ Contributions

Ning Zhu designed the study and drafted and revised the manuscript. Bingwu Huang performed the research and wrote the manuscript. Chengbin Huang, Liuyan Zhu, Lina Xie, and Yi Wang collected and analyzed the data. All authors read and approved the final manuscript.

Acknowledgments

This study was supported by Zhejiang Provincial Natural Science Foundation of China under Grant no. LQ20H020011.

Supplementary Materials

Known targets of TwHF and known therapeutic targets acting on CVD were shown in Supplementary Table 1. Known protein interactions of TwHF against CVD () were shown in Supplementary Table 2. (Supplementary Materials)

References

E. Olvera Lopez, B. D. Ballard, and A. Jan, “Cardiovascular Disease,” in StatPearls, Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC, 2020.
View at: Google Scholar
S. B. Dunbar, O. A. Khavjou, T. Bakas et al., “Projected costs of informal caregiving for cardiovascular disease: 2015 to 2035: a policy statement from the American Heart Association,” Circulation, vol. 137, no. 19, pp. e558–e577, 2018.
View at: Publisher Site | Google Scholar
S. Bansilal, J. M. Castellano, and V. Fuster, “Global burden of CVD: focus on secondary prevention of cardiovascular disease,” International journal of cardiology, vol. 201, pp. S1–S7, 2015.
View at: Publisher Site | Google Scholar
P. Joseph, D. Leong, M. McKee et al., “Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors,” Circulation research, vol. 121, no. 6, pp. 677–694, 2017.
View at: Publisher Site | Google Scholar
D. P. Leong, P. G. Joseph, M. McKee et al., “Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease,” Circulation research, vol. 121, no. 6, pp. 695–710, 2017.
View at: Publisher Site | Google Scholar
P. Hao, F. Jiang, J. Cheng, L. Ma, Y. Zhang, and Y. Zhao, “Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms,” Journal of the American College of Cardiology, vol. 69, no. 24, pp. 2952–2966, 2017.
View at: Publisher Site | Google Scholar
X. Zhao, Z. Liu, Z. Ren et al., “Triptolide inhibits pancreatic cancer cell proliferation and migration via down-regulating PLAU based on network pharmacology of _Tripterygium wilfordii Hook F_,” European journal of pharmacology, vol. 880, p. 173225, 2020.
View at: Publisher Site | Google Scholar
M. Xue, Z. Z. Jiang, T. Wu et al., “Anti-inflammatory effects and hepatotoxicity of Tripterygium-loaded solid lipid nanoparticles on adjuvant-induced arthritis in rats,” Phytomedicine, vol. 19, no. 11, pp. 998–1006, 2012.
View at: Publisher Site | Google Scholar
B. S. Choi, K. Sapkota, S. Kim, H. J. Lee, H. S. Choi, and S. J. Kim, “Antioxidant activity and protective effects of Tripterygium regelii extract on hydrogen peroxide-induced injury in human dopaminergic cells, SH-SY5Y,” Neurochemical Research, vol. 35, no. 8, pp. 1269–1280, 2010.
View at: Publisher Site | Google Scholar
W. H. Peng, G. L. Chen, Y. Zhou, S. Y. Fan, D. L. Fu, and Y. Wang, “Study of expression of circulating inflammatory factors in ACS rats with low dose of Tripterygium Wilfordii,” Hellenic Journal of Cardiology, vol. 59, no. 1, pp. 46-47, 2018.
View at: Publisher Site | Google Scholar
X. Li, N. Wu, L. Zou, and D. Jia, “Protective effect of celastrol on myocardial ischemia-reperfusion injury,” Anatolian journal of cardiology, vol. 18, no. 6, pp. 384–390, 2017.
View at: Publisher Site | Google Scholar
R. Li, K. Lu, Y. Wang et al., “Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression,” Biochemical and biophysical research communications, vol. 485, no. 1, pp. 69–75, 2017.
View at: Publisher Site | Google Scholar
H. Yu, L. Shi, S. Zhao et al., “Triptolide attenuates myocardial ischemia/reperfusion injuries in rats by inducing the activation of Nrf2/HO-1 defense pathway,” Cardiovascular toxicology, vol. 16, no. 4, pp. 325–335, 2016.
View at: Publisher Site | Google Scholar
C. Lu, X. Yu, K. Zuo et al., “Tripterine treatment improves endothelial progenitor cell function via integrin-linked kinase,” Cellular physiology and biochemistry, vol. 37, no. 3, pp. 1089–1103, 2015.
View at: Publisher Site | Google Scholar
B. Han, C.-Q. Ge, H.-G. Zhang et al., “Effects of tripterygium glycosides on restenosis following endovascular treatment,” Molecular medicine reports, vol. 13, no. 6, pp. 4959–4968, 2016.
View at: Publisher Site | Google Scholar
A. L. Hopkins, “Network pharmacology,” Nature biotechnology, vol. 25, no. 10, pp. 1110-1111, 2007.
View at: Publisher Site | Google Scholar
C. Lu, Z. Bing, Z. Bi et al., “Top-100 most cited publications concerning network pharmacology: a bibliometric analysis,” Evidence-based complementary and alternative medicine, vol. 2019, Article ID 1704816, 7 pages, 2019.
View at: Publisher Site | Google Scholar
P. Li, J. Chen, J. Wang et al., “Systems pharmacology strategies for drug discovery and combination with applications to cardiovascular diseases,” Journal of Ethnopharmacology, vol. 151, no. 1, pp. 93–107, 2014.
View at: Publisher Site | Google Scholar
J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of cheminformatics, vol. 6, no. 1, 2014.
View at: Publisher Site | Google Scholar
F. Liu, Y. Li, M. Li et al., “Study on mechanism of iridoid glycosides derivatives from Fructus Gardeniae in Jiangxi Province by network pharmacology,” Evidence-based complementary and alternative medicine, vol. 2020, Article ID 4062813, 12 pages, 2020.
View at: Publisher Site | Google Scholar
L. Huang, D. Xie, Y. Yu et al., “TCMID 2.0: a comprehensive resource for TCM,” Nucleic acids research, vol. 46, no. D1, pp. D1117–d1120, 2018.
View at: Publisher Site | Google Scholar
J. Xu, F. Wang, J. Guo et al., “Pharmacological mechanisms underlying the neuroprotective effects of Alpinia oxyphylla Miq. on Alzheimer's disease,” International journal of molecular sciences, vol. 21, no. 6, p. 2071, 2020.
View at: Publisher Site | Google Scholar
A. Daina, O. Michielin, and V. Zoete, “SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules,” Nucleic acids research, vol. 47, no. W1, pp. W357–w364, 2019.
View at: Publisher Site | Google Scholar
D. S. Wishart, Y. D. Feunang, A. C. Guo et al., “DrugBank 5.0: a major update to the DrugBank database for 2018,” Nucleic acids research, vol. 46, no. D1, pp. D1074–d1082, 2018.
View at: Publisher Site | Google Scholar
J. S. Amberger and A. Hamosh, “Searching Online Mendelian Inheritance in Man (OMIM): a knowledgebase of human genes and genetic phenotypes,” Current protocols in bioinformatics, vol. 58, no. 1, 2017.
View at: Publisher Site | Google Scholar
G. Stelzer, N. Rosen, I. Plaschkes et al., “The GeneCards suite: from gene data mining to disease genome sequence analyses,” Current protocols in bioinformatics, vol. 54, no. 1, 2016.
View at: Publisher Site | Google Scholar
M. Kuhn, D. Szklarczyk, A. Franceschini et al., “STITCH 2: an interaction network database for small molecules and proteins,” Nucleic acids research, vol. 38, suppl_1, pp. D552–D556, 2010.
View at: Publisher Site | Google Scholar
J. A. C. K. Blake, M. E. Dolan, H. J. Drabkin et al., “Gene ontology consortium: going forward,” Nucleic acids research, vol. 43, pp. D1049–D1056, 2015.
View at: Publisher Site | Google Scholar
M. Kanehisa, M. Furumichi, M. Tanabe, Y. Sato, and K. Morishima, “KEGG: new perspectives on genomes, pathways, diseases and drugs,” Nucleic acids research, vol. 45, no. D1, pp. D353–d361, 2017.
View at: Publisher Site | Google Scholar
P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.
View at: Publisher Site | Google Scholar
R. Li, C. Guo, Y. Li, Z. Qin, and W. Huang, “Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study,” Briefings in bioinformatics, vol. 22, 2021.
View at: Publisher Site | Google Scholar
J. Zhang, H. Li, Y. Zhang, C. Zhao, Y. Zhu, and M. Han, “Uncovering the pharmacological mechanism of stemazole in the treatment of neurodegenerative diseases based on a network pharmacology approach,” International journal of molecular sciences, vol. 21, no. 2, p. 427, 2020.
View at: Publisher Site | Google Scholar
X. Song, Y. Zhang, E. Dai, L. Wang, and H. Du, “Prediction of triptolide targets in rheumatoid arthritis using network pharmacology and molecular docking,” International immunopharmacology, vol. 80, 2020.
View at: Publisher Site | Google Scholar
W. Zhou, Y. Wang, A. Lu, and G. Zhang, “Systems pharmacology in small molecular drug discovery,” International journal of molecular sciences, vol. 17, no. 2, p. 246, 2016.
View at: Publisher Site | Google Scholar
S. Ye, W. Luo, Z. A. Khan et al., “Celastrol attenuates angiotensin II-induced cardiac remodeling by targeting STAT3,” Circulation research, vol. 126, no. 8, pp. 1007–1023, 2020.
View at: Publisher Site | Google Scholar
S. der Sarkissian, J. F. Cailhier, M. Borie et al., “Celastrol protects ischaemic myocardium through a heat shock response with up-regulation of haeme oxygenase-1,” British journal of pharmacology, vol. 171, no. 23, pp. 5265–5279, 2014.
View at: Publisher Site | Google Scholar
M. Cheng, G. Wu, Y. Song et al., “Celastrol-induced suppression of the MiR-21/ERK signalling pathway attenuates cardiac fibrosis and dysfunction,” Cellular physiology and biochemistry, vol. 38, no. 5, pp. 1928–1938, 2016.
View at: Publisher Site | Google Scholar
F. Liu, H. Zhang, Y. Li, and X. Lu, “Nobiletin suppresses oxidative stress and apoptosis in H9c2 cardiomyocytes following hypoxia/reoxygenation injury,” European journal of pharmacology, vol. 854, pp. 48–53, 2019.
View at: Publisher Site | Google Scholar
B. F. Zhang, H. Jiang, J. Chen et al., “Nobiletin ameliorates myocardial ischemia and reperfusion injury by attenuating endoplasmic reticulum stress-associated apoptosis through regulation of the PI3K/AKT signal pathway,” International immunopharmacology, vol. 73, pp. 98–107, 2019.
View at: Publisher Site | Google Scholar
X. Guo, M. Xue, C. J. Li et al., “Protective effects of triptolide on TLR4 mediated autoimmune and inflammatory response induced myocardial fibrosis in diabetic cardiomyopathy,” Journal of ethnopharmacology, vol. 193, pp. 333–344, 2016.
View at: Publisher Site | Google Scholar
Z. Liang, S. Leo, H. Wen, M. Ouyang, W. Jiang, and K. Yang, “Triptolide improves systolic function and myocardial energy metabolism of diabetic cardiomyopathy in streptozotocin-induced diabetic rats,” BMC cardiovascular disorders, vol. 15, no. 1, 2015.
View at: Publisher Site | Google Scholar
R. Negrão, D. Duarte, R. Costa, and R. Soares, “Isoxanthohumol modulates angiogenesis and inflammation via vascular endothelial growth factor receptor, tumor necrosis factor alpha and nuclear factor kappa B pathways,” BioFactors, vol. 39, no. 6, pp. 608–622, 2013.
View at: Publisher Site | Google Scholar
C. Li, Y. Liu, Z. Xie, Q. Lu, and S. Luo, “Stigmasterol protects against Ang II-induced proliferation of the A7r5 aortic smooth muscle cell-line,” Food & function, vol. 6, no. 7, pp. 2266–2272, 2015.
View at: Publisher Site | Google Scholar
H. Feng, J. Cao, G. Zhang, and Y. Wang, “Kaempferol attenuates cardiac hypertrophy via regulation of ASK1/MAPK signaling pathway and oxidative stress,” Planta Medica, vol. 83, no. 10, pp. 837–845, 2017.
View at: Publisher Site | Google Scholar
L. Zhang, Z. Guo, Y. Wang, J. Geng, and S. Han, “The protective effect of kaempferol on heart via the regulation of Nrf2, NF-κβ, and PI3K/Akt/GSK-3β signaling pathways in isoproterenol-induced heart failure in diabetic rats,” Drug development research, vol. 80, no. 3, pp. 294–309, 2019.
View at: Publisher Site | Google Scholar
P. Abeyrathna and Y. Su, “The critical role of Akt in cardiovascular function,” Vascular pharmacology, vol. 74, pp. 38–48, 2015.
View at: Publisher Site | Google Scholar
G. Yu, Z. Luo, Y. Zhou et al., “Uncovering the pharmacological mechanism of Carthamus tinctorius L. on cardiovascular disease by a systems pharmacology approach,” Biomedicine & pharmacotherapy, vol. 117, 2019.
View at: Publisher Site | Google Scholar
S. J. Leevers, B. Vanhaesebroeck, and M. D. Waterfield, “Signalling through phosphoinositide 3-kinases: the lipids take centre stage,” Current opinion in cell biology, vol. 11, no. 2, pp. 219–225, 1999.
View at: Publisher Site | Google Scholar
C. L. Carpenter, B. C. Duckworth, K. R. Auger, B. Cohen, B. S. Schaffhausen, and L. C. Cantley, “Purification and characterization of phosphoinositide 3-kinase from rat liver.,” The Journal of biological chemistry, vol. 265, no. 32, pp. 19704–19711, 1990.
View at: Publisher Site | Google Scholar
B. A. McLean, V. B. Patel, P. Zhabyeyev et al., “PI3Kα pathway inhibition with doxorubicin treatment results in distinct biventricular atrophy and remodeling with right ventricular dysfunction,” Journal of the American Heart Association, vol. 8, no. 9, p. e010961, 2019.
View at: Publisher Site | Google Scholar
The Cancer Genome Atlas Network, “Comprehensive molecular portraits of human breast tumours,” Nature, vol. 490, no. 7418, pp. 61–70, 2012.
View at: Publisher Site | Google Scholar
G. Pearson, F. Robinson, T. Beers Gibson et al., “Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions,” Endocrine reviews, vol. 22, no. 2, pp. 153–183, 2001.
View at: Publisher Site | Google Scholar
Y. Wang, X. Zhang, L. Gao et al., “Cortistatin exerts antiproliferation and antimigration effects in vascular smooth muscle cells stimulated by Ang II through suppressing ERK1/2, p38 MAPK, JNK and ERK5 signaling pathways,” Annals of translational medicine, vol. 7, no. 20, p. 561, 2019.
View at: Publisher Site | Google Scholar
Y. Taniyama, M. Ushio-Fukai, H. Hitomi et al., “Role of p38 MAPK and MAPKAPK-2 in angiotensin II-induced Akt activation in vascular smooth muscle cells,” American journal of physiology Cell physiology, vol. 287, no. 2, pp. C494–C499, 2004.
View at: Publisher Site | Google Scholar
Y. Kyotani, J. Zhao, S. Tomita et al., “Olmesartan inhibits angiotensin II-induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways,” Journal of Pharmacological Sciences, vol. 113, no. 2, pp. 161–168, 2010.
View at: Publisher Site | Google Scholar
C. Visconte, J. Canino, G. F. Guidetti et al., “Amyloid precursor protein is required for in vitro platelet adhesion to amyloid peptides and potentiation of thrombus formation,” Cellular signalling, vol. 52, pp. 95–102, 2018.
View at: Publisher Site | Google Scholar
I. Canobbio, C. Visconte, S. Momi et al., “Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice,” Blood, vol. 130, no. 4, pp. 527–536, 2017.
View at: Publisher Site | Google Scholar
V. Kolovou, A. Tsipis, C. Mihas et al., “Tumor protein p53 (TP53) gene and left main coronary artery disease,” Angiology, vol. 69, no. 8, pp. 730–735, 2018.
View at: Publisher Site | Google Scholar
K. Lemmens, K. Doggen, and G. W. De Keulenaer, “Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure,” Circulation, vol. 116, no. 8, pp. 954–960, 2007.
View at: Publisher Site | Google Scholar
O. Odiete, M. F. Hill, and D. B. Sawyer, “Neuregulin in cardiovascular development and disease,” Circulation research, vol. 111, no. 10, pp. 1376–1385, 2012.
View at: Publisher Site | Google Scholar
J. Huang, C. Cai, T. Zheng et al., “Endothelial scaffolding protein ENH (enigma homolog protein) promotes PHLPP2 (pleckstrin homology domain and leucine-rich repeat protein phosphatase 2)-mediated dephosphorylation of AKT1 and eNOS (endothelial NO synthase) promoting vascular remodeling,” Arteriosclerosis, thrombosis, and vascular biology, vol. 40, no. 7, pp. 1705–1721, 2020.
View at: Publisher Site | Google Scholar
L. Kovacs, Y. Cao, W. Han et al., “PFKFB3 in smooth muscle promotes vascular remodeling in pulmonary arterial hypertension,” American journal of respiratory and critical care medicine, vol. 200, no. 5, pp. 617–627, 2019.
View at: Publisher Site | Google Scholar
D. M. Taglieri, M. Ushio-Fukai, and M. M. Monasky, “P21-activated kinase in inflammatory and cardiovascular disease,” Cellular signalling, vol. 26, no. 9, pp. 2060–2069, 2014.
View at: Publisher Site | Google Scholar
H. Shimokawa, S. Sunamura, and K. Satoh, “RhoA/Rho-kinase in the cardiovascular system,” Circulation research, vol. 118, no. 2, pp. 352–366, 2016.
View at: Publisher Site | Google Scholar
X. Su, C. Yuan, L. Wang et al., “The beneficial effects of saffron extract on potential oxidative stress in cardiovascular diseases,” Oxidative medicine and cellular longevity, vol. 2021, Article ID 6699821, 14 pages, 2021.
View at: Publisher Site | Google Scholar
T. Donia and A. Khamis, “Management of oxidative stress and inflammation in cardiovascular diseases: mechanisms and challenges,” Environmental science and pollution research international, vol. 28, no. 26, pp. 34121–34153, 2021.
View at: Publisher Site | Google Scholar
E. Dubois-Deruy, V. Peugnet, A. Turkieh, and F. Pinet, “Oxidative stress in cardiovascular diseases,” Antioxidants, vol. 9, no. 9, p. 864, 2020.
View at: Publisher Site | Google Scholar
S. Tiwari and U. N. Dwivedi, “Discovering innovative drugs targeting both cancer and cardiovascular disease by shared protein-protein interaction network analyses,” Omics: a journal of integrative biology, vol. 23, no. 9, pp. 417–425, 2019.
View at: Publisher Site | Google Scholar
A. A. Ivanov, F. R. Khuri, and H. Fu, “Targeting protein-protein interactions as an anticancer strategy,” Trends in pharmacological sciences, vol. 34, no. 7, pp. 393–400, 2013.
View at: Publisher Site | Google Scholar
A. Sarajlić, V. Janjić, N. Stojković, D. Radak, and N. Pržulj, “Network topology reveals key cardiovascular disease genes,” PLoS One, vol. 8, no. 8, article e71537, 2013.
View at: Publisher Site | Google Scholar
C. Zhang, X. J. He, L. Li, C. Lu, and A. P. Lu, “Effect of the natural product triptolide on pancreatic cancer: a systematic review of preclinical studies,” Frontiers in pharmacology, vol. 8, 2017.
View at: Publisher Site | Google Scholar
L. Wen, Y. Chen, L. L. Zeng et al., “Triptolide induces cell apoptosis by targeting H3K4me3 and downstream effector proteins in KM3 multiple myeloma cells,” Current pharmaceutical biotechnology, vol. 17, no. 2, pp. 147–160, 2015.
View at: Publisher Site | Google Scholar
O. Fuchs, “Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies,” Current molecular pharmacology, vol. 3, no. 3, pp. 98–122, 2010.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2021 Bingwu Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

539

Downloads

1130

Citations